Philogen (PHIL) H2 2025 earnings summary

Executive summary

• Achieved strong financial performance in 2025, reporting a net profit of €229.7 million and cash and cash equivalents of €379.2 million at year-end.

• Total revenue reached €320.1 million for FY2025, up €242.5 million year-over-year, driven by a €300 million upfront payment from a licensing deal with RayzeBio (BMS Group) for OncoACP3 targeting prostate cancer.

• Announced a dividend of €0.70 per share, reflecting confidence in financial health and subject to shareholder approval.

• Advanced clinical pipeline with multiple registration-enabling trials in oncology, notably for Nidlegy and Fibromun.

• Maintained robust partnerships, notably with Sun Pharma, Bracco Group, and RayzeBio/Bristol Myers Squibb.

Financial highlights

• Revenue from contracts with customers rose 325% year-over-year to €314.3 million, mainly due to the RayzeBio licensing agreement.

• EBITDA surged to €261.6 million, with an EBITDA margin of 83.2%.

• Net profit for 2025 was €229.7 million.

• Cash and cash equivalents at year-end totaled €379.2 million.

• Monthly spending in 2025 was around €4 million, with expectations to remain stable or slightly increase in 2026.

Outlook and guidance

• Submission for European marketing authorization of Nidlegy targeted for July 2026, with a decision expected by mid-2027.

• U.S. trial for Nidlegy progressing, aiming for subsequent marketing application.

• FIBROSARC-2 phase III trial in soft tissue sarcoma to launch after regulatory alignment, with clinical trial application expected in Q3 2026.

• Expansion of clinical pipeline with new studies in BCC, CSCC, and glioblastoma, and further development of small molecule platforms.

• Continued investment in data science and AI to enhance operational efficiency and accelerate drug discovery.